Highest-materiality recent filing
Amphastar subsidiary IMS receives FDA warning letter for CGMP violations at South El Monte facility
Warning letter dated July 2, 2026, follows December 2025 FDA inspection of IMS's South El Monte, CA facility.
Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42
Net revenues flat at $171.2M vs $170.5M YoY.
Amphastar Q4 revenue $183.1M, down 1.8% YoY; GAAP EPS $0.51 vs $0.74
Full year 2025 net revenue $719.9M, down 1.6% YoY from $732.0M.
Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal
Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.
Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96
Net revenues of $191.8M, flat YoY vs $191.2M.
Amphastar licenses three novel peptides from Anji for up to $453M total
Exclusive license for three proprietary peptides targeting oncology and ophthalmology in U.S. and Canada.
Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%
Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).
Amphastar Q1 2025 GAAP net income $25.3M ($0.51 EPS); adjusted EPS $0.74
Net revenues $170.5M, down from $171.8M in Q1 2024.
Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86
Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).
Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96
Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.
Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY
Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.
Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04
Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.
Amphastar Q4 net revenue $178.1M, GAAP EPS $0.68; FY revenue $644.4M
Q4 2023 net revenue $178.1M (+32% YoY); GAAP net income $36.2M ($0.68 EPS).
Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15
Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).
Amphastar issues $345M 2% convertible senior notes due 2029; repays $200M term loan, buys $50M stock
$345M aggregate principal (incl. $45M greenshoe exercised) of 2.00% convertible senior notes due 2029, sold via Rule 144A.
Amphastar files BAQSIMI financials: 2022 revenue $139.3M, revenue less direct expenses $59.8M
BAQSIMI 2022 revenue $139.3M (up 23% YoY from $113.2M); revenue less direct expenses $59.8M vs -$2.3M in 2021.
Amphastar Q2 2023 revenue $145.7M, GAAP EPS $0.49, adj. EPS $0.65
Net revenues $145.7M for Q2 2023, up 18% from $123.5M in Q2 2022.
Amphastar completes $500M acquisition of BAQSIMI from Lilly; funds with $500M term loan
Paid $500M cash at closing; also owes $125M guaranteed payment in one year plus up to $450M contingent milestones.
Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62
Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).
Amphastar to buy Lilly's BAQSIMI for $500M cash, $125M guarantee, up to $450M milestones
Purchase price: $500M cash at closing, $125M guaranteed payment at 1-year anniversary, plus up to $450M in sales-based milestones.
Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)
Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).
Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY
Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).
Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33
Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).
Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10
Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).
Amphastar Q4 revenue $120.9M, GAAP EPS $0.39; full-year net income $62.1M
Q4 net revenues $120.9M vs $95.9M in Q4 2020, up 26%; GAAP net income $19.8M vs loss of $6.3M.
Amphastar Q3 net revenues up 34% YoY to $112.2M; GAAP EPS $0.59 vs $0.08
Net revenues $112.2M (Q3 2021), up 34% from $83.4M in Q3 2020.
appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors
appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors
On August 19, 2021, David Maris tendered his resignation to the Board of Directors (the “ Board ”) of Amphastar Pharmaceuticals, Inc. (the “ Company ”) effective immediately.
On August 5, 2021, Richard Koo announced his retirement from the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”) effective as of September 30, 2021.
Max materiality 0.85 · Median 0.60 · Most common event earnings